compound semaglutide discontinued Is Being Discontinued? GLP-1 Access Guide Compounded Semaglutide - Green Relief

If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns

Author: Shane Straight, Principal Chemist, OPS Peptide Science Reviewed: May 2026

For example, if you are allergic to certain ingredients in semaglutide, compounding pharmacies can exclude those ingredients and produce an allergen-free compounded version of semaglutide

Liraglutide (NCT01843075 and NCT02953665), lixisenatide (NCT03439943), semaglutide (NCT04777396 and NCT03659682) and exenatide (NCT01255163 and NCT01971242) are being tested in clinical trials for Alzheimer's and Parkinson's diseases

Nonetheless, gastrointestinal adverse symptoms (e.g., nausea, vomiting) persist often, and long-term safety data are still being examined

The most commonly reported adverse events in Phase 2 and Phase 3 trials were gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation